Back to News
Market Impact: 0.45
Disc Medicine's Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Disc Medicine reported positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in adults and adolescents with erythropoietic protoporphyria. The investigational therapy met all primary and secondary endpoints; the article provided no numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
IRON0.90
More News
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Disc Medicine stock soars: take profit or buy into strength?
- BMO raises Disc Medicine stock price target on positive trial data
- Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
- Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion